Asunto(s)
Terapia Cognitivo-Conductual/estadística & datos numéricos , Trastorno Depresivo Mayor/terapia , Prescripciones de Medicamentos/estadística & datos numéricos , Terapia Electroconvulsiva/estadística & datos numéricos , Necesidades y Demandas de Servicios de Salud , Hospitales/estadística & datos numéricos , Guías de Práctica Clínica como Asunto , Estudios Transversales , Investigación sobre Servicios de Salud , Humanos , Japón , Polifarmacia , Indicadores de Calidad de la Atención de Salud , Estudios RetrospectivosRESUMEN
BACKGROUND: Guideline for Pharmacological Therapy for Schizophrenia was published by the Japanese Society of Neuropsychopharmacology in 2015. "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project aimed to standardize medical practice using quality indicators (QIs) as indices to evaluate the quality of medical practice. In this study, we have reported the quality indicator values of prescription before the beginning of the guideline lectures in the EGUIDE project to ascertain the baseline status of treating patients with schizophrenia. METHODS: A cross-sectional, retrospective case record survey was conducted, involving 1164 patients with schizophrenia at the time of discharge. We checked all types and dosage of psychotropic drugs. RESULTS: Forty-three percent of patients had antipsychotic polypharmacy, and substantial concomitant medication was observed (antidepressants; 8%, mood stabilizers: 37%, anxiolytics or hypnotics: 68%). CONCLUSIONS: In the results obtained in this study, we plant to report changes in the effectiveness of education in the EGUIDE project near the future.
Asunto(s)
Guías de Práctica Clínica como Asunto/normas , Pautas de la Práctica en Medicina/normas , Prescripciones/normas , Psiquiatría/normas , Indicadores de Calidad de la Atención de Salud/normas , Esquizofrenia/tratamiento farmacológico , Ansiolíticos/administración & dosificación , Antidepresivos/administración & dosificación , Antipsicóticos/administración & dosificación , Estudios Transversales , Femenino , Humanos , Japón/epidemiología , Masculino , Polifarmacia , Pautas de la Práctica en Medicina/tendencias , Psiquiatría/educación , Psiquiatría/tendencias , Indicadores de Calidad de la Atención de Salud/tendencias , Estudios Retrospectivos , Esquizofrenia/epidemiología , Encuestas y CuestionariosRESUMEN
The largest task for psychiatry in Japan today is the deinstitutionalization of patients with psychiatric disorders. In Japan, all citizens are covered by a national health plan, and about 70% of the total cost is covered by the national health insurance scheme. At present, however, there is still no category for early intervention in the national health reimbursement schedule. Recent research has shown that the mean duration of untreated psychosis (DUP) at seven university hospitals in Japan was 17.6 months. We present data using case vignettes suggesting that pharmacotherapy might be overused in prodromal cases. The concept of an At-Risk Mental State (ARMS)/prodromal state might not yet be widely recognized among Japanese psychiatrists. We outline early intervention initiatives in Japan; The Japanese Society for Prevention and Early Intervention in Psychiatry (JSEIP), and a representative early intervention facility for young people is the "Il Bosco" in Tokyo. There are several leading centers for early intervention research and practice in Japan. Most of them are driven by university departments of psychiatry with respect to both research and clinical activities. The development of services for early intervention is expected to reduce stigmatization, prevent suicide among young persons, and promote general knowledge about mental health. There are several common or similar issues among Asian countries, including service systems, community attitudes to psychiatric illness including stigma, and dependence on pharmacotherapy.
Asunto(s)
Antipsicóticos/uso terapéutico , Intervención Médica Temprana/estadística & datos numéricos , Pautas de la Práctica en Medicina , Síntomas Prodrómicos , Trastornos Psicóticos/terapia , Esquizofrenia/terapia , Intervención Médica Temprana/economía , Humanos , Japón , Servicios de Salud Mental , Programas Nacionales de Salud/economía , Psiquiatría , Trastornos Psicóticos/economía , Esquizofrenia/economía , Estigma Social , Estereotipo , Suicidio , Encuestas y Cuestionarios , Factores de TiempoRESUMEN
The purpose of the present study was to investigate regional cerebral blood flow (rCBF) changes in a patient with very-late-onset schizophrenia-like psychosis (VLOS) with catatonia. A 64-year-old woman developed catatonia after experiencing persecutory delusions. The patient's rCBF was examined using single photon emission computed tomography (SPECT) with easy Z-score imaging system. Before treatment, hypoperfusion was observed in the striatum and the thalamus, whereas hyperperfusion was observed in the left lateral frontal cortex and the left temporal cortex. After treatment, the disproportions in rCBF disappeared, and hyperperfusion was observed in the motor cortex. Sequential SPECT findings suggest that rCBF abnormalities may be correlated with the symptomatology of catatonia in patients with VLOS.